Investor Relations

Investors

Investor Relations

Corporate Profile

Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented CDA technology and proprietary cancer-detection device.

Press Releases

Sep 15, 2020

AnPac Bio Receives Major Immunology Testing Contract

SAN JOSE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that the Company

Sep 10, 2020

AnPac Bio Reports First Six Months of 2020 Financial Results

SAN JOSE, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its financial results for the six months ended June 30, 2020.

Sep 04, 2020

AnPac Bio Announces Positive Results from a Multi-Year Lung Cancer Prognosis and Recurrence Clinical Study

SAN JOSE, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today positive results from a successfully completed a multi-year lung

Stock Quote

Change

Volume

52 Week High

52 Week Low

Sep 20, 2020 4:05 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

AnPac Bio First Six Months 2020 Financial Results

Sep 10, 2020 at 8:00 AM EDT

View Webcast

Investors

Investor Relations

Corporate Profile

Stock Quote

Quick Links

Contact Information